Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

XNCR vs BOLD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XNCR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

XNCR Overall Winner 6-Pillar Tally: XNCR 5 – 1 BOLD Matrix Metrics: XNCR 6 – 4 BOLD

As of Nov 20, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). XNCR carries a Unified Composite Score of 36.3/100 (SELL) at $33.26 (68.0x Forward P/E, -72.7% operating margin), whereas BOLD carries 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although XNCR compares more favorably head-to-head, both XNCR (36.3/100 SELL) and BOLD (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 53.5); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XNCR vs BOLD
XNCR NASDAQ Head-to-Head Winner
Xencor, Inc.
Pharmaceutical Preparations
$33.26
-2.21% 1D
Market Cap $2.6B
TTM Revenue $200M
Forward P/E 68.0x
Beta / 30D Vol 1.18β · 86% Vol
Unified Composite Score
36.3 / 100 SELL
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (11.7% over 20 days), RSI 53
RSI-14: 53.5 · SMA20: $33.90 · SMA50: $28.26
BOLD NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.08β · 28% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $2.43 · SMA50: $2.52

6-Pillar Scorecard Institutional Category Breakdown (XNCR 5 – 1 BOLD)

Columns: Metric · XNCR · BOLD
1. Valuation Multiples XNCR
Forward P/E 68.0x N/M
Trailing P/E 68.0x N/M
PEG Ratio N/M N/M
EV / Revenue 13.2x N/M
2. Growth & Scale XNCR
Revenue Growth (YoY) +454.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $200M N/A
Market Cap $2.6B $56.2M
3. Profitability & Quality BOLD
Gross Margin -42.5% N/A
Operating Margin -72.7% 0.0%
Net Profit Margin -58.8% 0.0%
Return on Equity (ROE) -19.9% -64.6%
4. Balance Sheet & Cash Flow XNCR
Cash Generation (TTM) -$176M -$48M
Cash Flow Margin -88.0% N/A
Net Cash / Leverage $101M Net Debt (0.29x D/E) $31M Net Debt (0.56x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XNCR
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 88.4% (11th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat XNCR
OpEx & R&D Intensity 30.2% of Rev ($61M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XNCR (6) vs BOLD (4)
Institutional Metric XNCR BOLD Criterion Row Edge
Market Capitalization
Scale
$2.6B $56.2M Larger Scale XNCR
Trailing P/E Ratio
Valuation
68.0x N/M Lower Multiple XNCR
Forward P/E Ratio
Valuation
68.0x N/M Lower Multiple XNCR
Revenue Growth (YoY)
Growth
+454.9% +0.0% Higher Growth XNCR
Operating Margin (TTM)
Profitability
-72.7% 0.0% Higher Margin BOLD
Net Profit Margin
Profitability
-58.8% 0.0% Higher Margin BOLD
Return on Equity (ROE)
Capital Efficiency
-19.9% -64.6% Higher ROE XNCR
52-Week Range Position
Momentum
76% ($10–$41) 62% ($1–$3) Stronger Trend XNCR
Beta / 30D Volatility
Risk Regime
1.18β · 86% Vol -0.08β · 28% Vol Lower Realized Risk BOLD
Unified Institutional Score
Composite Signal
36.3 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite BOLD
Trailing 12M Revenue (USD)
Operating Scale
$200M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 13.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$176M ($101M Net Debt (0.29x D/E)) -$48M ($31M Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XNCR +33.64 pp
XNCR: +28.72% · BOLD: -4.92%
3M Horizon XNCR +36.33 pp
XNCR: +14.71% · BOLD: -21.62%
6M Horizon XNCR +132.97 pp
XNCR: +194.08% · BOLD: +61.11%
1Y Horizon XNCR +9.17 pp
XNCR: +110.91% · BOLD: +101.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XNCR vs BOLD. Trailing 12-month operating profitability (XNCR -72.7% vs BOLD 0.0%) and valuation multiples (XNCR 68.0x vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

XNCR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$200M
Gross Margin-42.5%
Op. Margin-72.7%
ROE / Fwd P/E-19.9% · 68.0x
BOLD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XNCR BREAKOUT
62d in phase · OBV DISTRIBUTION
Current IV 88.4%
IV Percentile 11th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact XNCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XNCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.6B market capitalization and -72.7% operating margin.
OpEx & R&D Reinvestment 30.2% of Rev ($61M)
90D Engineering Disclosures 0 Published
BOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XNCR vs BOLD Key Questions & Quantitative Answers

As of Nov 20, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). XNCR carries a Unified Composite Score of 36.3/100 (SELL) at $33.26 (68.0x Forward P/E, -72.7% operating margin), whereas BOLD carries 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although XNCR compares more favorably head-to-head, both XNCR (36.3/100 SELL) and BOLD (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 53.5); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XNCR leads the Growth & Scale pillar: XNCR posts +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin), compared with BOLD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, XNCR generates $200M in USD-normalized revenue versus N/A for BOLD. In operating R&D and SG&A reinvestment, XNCR deploys 30.2% of Rev ($61M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BOLD.

XNCR screens cheaper on headline valuation multiples. XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 13.2x EV/Revenue (-88.0% FCF margin), whereas BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XNCR (-19.9% ROE) versus BOLD (-64.6% ROE) capital efficiency.

In options market volatility and institutional positioning, XNCR carries 88.4% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (1.18β · 86% Vol realized risk). By comparison, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.